|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DHX9 |
Gene summary for DHX9 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DHX9 | Gene ID | 1660 |
| Gene name | DExH-box helicase 9 | |
| Gene Alias | DDX9 | |
| Cytomap | 1q25.3 | |
| Gene Type | protein-coding | GO ID | GO:0000375 | UniProtAcc | B3KU66 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 1660 | DHX9 | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.64e-02 | -3.07e-01 | 0.0155 |
| 1660 | DHX9 | HTA11_866_2000001011 | Human | Colorectum | AD | 1.16e-02 | -1.61e-01 | -0.1001 |
| 1660 | DHX9 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 3.66e-09 | 5.75e-01 | 0.294 |
| 1660 | DHX9 | A015-C-203 | Human | Colorectum | FAP | 1.15e-17 | -2.52e-01 | -0.1294 |
| 1660 | DHX9 | A002-C-201 | Human | Colorectum | FAP | 7.88e-06 | -1.83e-01 | 0.0324 |
| 1660 | DHX9 | A002-C-203 | Human | Colorectum | FAP | 1.97e-02 | -1.28e-01 | 0.2786 |
| 1660 | DHX9 | A001-C-119 | Human | Colorectum | FAP | 6.00e-04 | -2.34e-01 | -0.1557 |
| 1660 | DHX9 | A001-C-108 | Human | Colorectum | FAP | 1.31e-11 | -2.87e-01 | -0.0272 |
| 1660 | DHX9 | A002-C-205 | Human | Colorectum | FAP | 5.84e-13 | -3.09e-01 | -0.1236 |
| 1660 | DHX9 | A015-C-006 | Human | Colorectum | FAP | 3.13e-08 | -2.44e-01 | -0.0994 |
| 1660 | DHX9 | A015-C-106 | Human | Colorectum | FAP | 1.14e-09 | -2.12e-01 | -0.0511 |
| 1660 | DHX9 | A002-C-114 | Human | Colorectum | FAP | 5.45e-11 | -3.06e-01 | -0.1561 |
| 1660 | DHX9 | A015-C-104 | Human | Colorectum | FAP | 5.70e-20 | -2.89e-01 | -0.1899 |
| 1660 | DHX9 | A001-C-014 | Human | Colorectum | FAP | 7.68e-09 | -2.11e-01 | 0.0135 |
| 1660 | DHX9 | A002-C-016 | Human | Colorectum | FAP | 1.61e-11 | -2.49e-01 | 0.0521 |
| 1660 | DHX9 | A015-C-002 | Human | Colorectum | FAP | 1.70e-06 | -2.55e-01 | -0.0763 |
| 1660 | DHX9 | A001-C-203 | Human | Colorectum | FAP | 3.43e-05 | -1.48e-01 | -0.0481 |
| 1660 | DHX9 | A002-C-116 | Human | Colorectum | FAP | 2.34e-22 | -3.38e-01 | -0.0452 |
| 1660 | DHX9 | A014-C-008 | Human | Colorectum | FAP | 2.02e-07 | -2.25e-01 | -0.191 |
| 1660 | DHX9 | A018-E-020 | Human | Colorectum | FAP | 1.19e-10 | -3.19e-01 | -0.2034 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00467004 | Colorectum | FAP | heterocycle catabolic process | 98/2622 | 445/18723 | 2.36e-06 | 9.21e-05 | 98 |
| GO:00510544 | Colorectum | FAP | positive regulation of DNA metabolic process | 53/2622 | 201/18723 | 2.55e-06 | 9.82e-05 | 53 |
| GO:00323884 | Colorectum | FAP | positive regulation of intracellular transport | 53/2622 | 202/18723 | 2.99e-06 | 1.10e-04 | 53 |
| GO:00194394 | Colorectum | FAP | aromatic compound catabolic process | 100/2622 | 467/18723 | 6.75e-06 | 2.08e-04 | 100 |
| GO:00510984 | Colorectum | FAP | regulation of binding | 81/2622 | 363/18723 | 1.04e-05 | 2.97e-04 | 81 |
| GO:00485244 | Colorectum | FAP | positive regulation of viral process | 23/2622 | 65/18723 | 1.24e-05 | 3.41e-04 | 23 |
| GO:00468224 | Colorectum | FAP | regulation of nucleocytoplasmic transport | 32/2622 | 106/18723 | 1.30e-05 | 3.53e-04 | 32 |
| GO:19033124 | Colorectum | FAP | negative regulation of mRNA metabolic process | 29/2622 | 92/18723 | 1.31e-05 | 3.53e-04 | 29 |
| GO:19023693 | Colorectum | FAP | negative regulation of RNA catabolic process | 25/2622 | 75/18723 | 1.74e-05 | 4.42e-04 | 25 |
| GO:00190804 | Colorectum | FAP | viral gene expression | 29/2622 | 94/18723 | 2.07e-05 | 5.05e-04 | 29 |
| GO:00323864 | Colorectum | FAP | regulation of intracellular transport | 75/2622 | 337/18723 | 2.38e-05 | 5.60e-04 | 75 |
| GO:00510994 | Colorectum | FAP | positive regulation of binding | 44/2622 | 173/18723 | 4.52e-05 | 9.40e-04 | 44 |
| GO:19013614 | Colorectum | FAP | organic cyclic compound catabolic process | 101/2622 | 495/18723 | 4.87e-05 | 9.93e-04 | 101 |
| GO:00434893 | Colorectum | FAP | RNA stabilization | 21/2622 | 65/18723 | 1.33e-04 | 2.13e-03 | 21 |
| GO:20010204 | Colorectum | FAP | regulation of response to DNA damage stimulus | 51/2622 | 219/18723 | 1.40e-04 | 2.21e-03 | 51 |
| GO:00468244 | Colorectum | FAP | positive regulation of nucleocytoplasmic transport | 20/2622 | 62/18723 | 1.95e-04 | 2.83e-03 | 20 |
| GO:00064034 | Colorectum | FAP | RNA localization | 47/2622 | 201/18723 | 2.27e-04 | 3.22e-03 | 47 |
| GO:00342504 | Colorectum | FAP | positive regulation of cellular amide metabolic process | 39/2622 | 162/18723 | 4.02e-04 | 4.86e-03 | 39 |
| GO:00226134 | Colorectum | FAP | ribonucleoprotein complex biogenesis | 91/2622 | 463/18723 | 4.28e-04 | 5.12e-03 | 91 |
| GO:00016493 | Colorectum | FAP | osteoblast differentiation | 51/2622 | 229/18723 | 4.40e-04 | 5.22e-03 | 51 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DHX9 | SNV | Missense_Mutation | novel | c.1531N>T | p.Asp511Tyr | p.D511Y | Q08211 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A7-A5ZW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | CR |
| DHX9 | SNV | Missense_Mutation | c.2173N>T | p.Val725Phe | p.V725F | Q08211 | protein_coding | deleterious(0.04) | probably_damaging(0.998) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| DHX9 | SNV | Missense_Mutation | c.3280C>T | p.His1094Tyr | p.H1094Y | Q08211 | protein_coding | tolerated(1) | benign(0.157) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| DHX9 | SNV | Missense_Mutation | c.2714G>A | p.Arg905Gln | p.R905Q | Q08211 | protein_coding | deleterious(0.02) | probably_damaging(0.984) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| DHX9 | SNV | Missense_Mutation | novel | c.2202N>C | p.Gln734His | p.Q734H | Q08211 | protein_coding | deleterious(0) | probably_damaging(0.95) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| DHX9 | SNV | Missense_Mutation | rs754675901 | c.1582C>T | p.Arg528Cys | p.R528C | Q08211 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| DHX9 | SNV | Missense_Mutation | c.176G>A | p.Ser59Asn | p.S59N | Q08211 | protein_coding | tolerated(0.22) | benign(0.281) | TCGA-BH-A1F0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| DHX9 | SNV | Missense_Mutation | novel | c.929N>G | p.Leu310Arg | p.L310R | Q08211 | protein_coding | deleterious(0.01) | probably_damaging(0.97) | TCGA-C8-A8HQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| DHX9 | SNV | Missense_Mutation | c.2588G>A | p.Arg863His | p.R863H | Q08211 | protein_coding | deleterious(0.05) | probably_damaging(0.993) | TCGA-D8-A1JE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamicin | SD | |
| DHX9 | SNV | Missense_Mutation | c.67N>G | p.Ile23Val | p.I23V | Q08211 | protein_coding | tolerated(0.92) | benign(0.028) | TCGA-E9-A1NI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |